Biotech Value (fka )

[maytepper]

$SGEN Seattle Genetics: Positive Ph 3 AETHERA Trial Paves Path For Significant Market Potential, Says William Blair http://www.smarteranalyst.com/2014/09/29/seattle-genetics-positive-phase-3-aethera-trial-paves-path-significant-market-potential-says-william-blair/

[maytepper]

$OPK Oppenheimer Reiterates Outperform On Opko Health On The Heels Of Rayaldee Positive Top-Line Data http://www.smarteranalyst.com/2014/09/24/oppenheimer-reiterates-outperform-opko-health-heels-rayaldee-positive-top-line-data/

[maytepper]

$DXCM William Blair Assigns Outperform On Dexcom Shares http://www.smarteranalyst.com/2014/09/22/william-blair-assigns-outperform-dexcom-shares/

[maytepper]

$PETX Aratana: Public Offering Eliminates Financial Overhang, Says William Blair http://www.smarteranalyst.com/2014/09/22/aratana-public-offering-eliminates-financial-overhang-says-william-blair/

[maytepper]

$DVAX William Blair Reiterates Outperform On Dynavax Following Completion Of Enrollment In HBV-23 http://www.smarteranalyst.com/2014/09/22/william-blair-reiterates-outperform-dynavax-following-completion-enrollment-hbv-23/

[maytepper]

$BLUE Roth Capital Initiates Buy On Bluebird Bio; Sees 38% Upside For The Stock http://www.smarteranalyst.com/2014/09/22/roth-capital-initiates-buy-bluebird-bio-sees-38-upside-stock/

[maytepper]

$SPPI $CASI Roth Capital Reiterates Buy On Spectrum On The Back Of License Agreement With CASI http://www.smarteranalyst.com/2014/09/19/roth-capital-reiterates-buy-spectrum-back-license-agreement-casi/

[maytepper]

$RNA Roth Capital Sees 93% Upside In Prosensa But Financial Overhang Still Exist http://www.smarteranalyst.com/2014/09/19/roth-capital-sees-93-upside-prosensa-financial-overhang-still-exist/

[maytepper]

$SNGX Brean Capital Maintains Buy On Soligenix Following NIAID Contract Award http://www.smarteranalyst.com/2014/09/19/brean-capital-maintains-buy-soligenix-following-niaid-contract-award/

[maytepper]

$EGRX Cantor Fitzgerald Reiterates Sell On Endo Health, Increases PT To $56
http://www.smarteranalyst.com/2014/09/18/cantor-fitzgerald-maintains-buy-eagle-pharma-teva-removes-initial-lawsuit-files-another-one/

[maytepper]

$ENDP Cantor Fitzgerald Reiterates Sell On Endo Health, Increases PT To $56
http://www.smarteranalyst.com/2014/09/18/cantor-fitzgerald-reiterates-sell-endo-health-increases-pt-56/

[maytepper]

$SNGX Maxim Maintains Buy On Soligenix Following Preclinical Results http://www.smarteranalyst.com/2014/09/17/maxim-maintains-buy-on-soligenix-following-preclinical-results/

[maytepper]

$BLRX Maxim Group Maintains Buy On Biolinerx Following Presentation At The SOHO http://www.smarteranalyst.com/2014/09/17/maxim-group-maintains-buy-on-biolinerx-following-presentation-at-the-soho/

[maytepper]

$CTIC Janney Reiterates Buy On Cell Therapeutics Following Collaboration Agreement With Servier http://www.smarteranalyst.com/2014/09/17/janney-reiterates-buy-on-cell-therapeutics-following-collaboration-agreement-with-servier/